NDAORALTABLET
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
ALVAIZ (eltrombopag) by Teva is tpo-receptor agonist that interacts with the transmembrane domain of the human tpo-receptor (also known as cmpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production. First approved in 2023.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALVAIZ (eltrombopag) is an oral TPO-receptor agonist approved by the FDA in November 2023 that increases platelet production by activating the thrombopoietin receptor on megakaryocytes. It is indicated for patients with thrombocytopenia who require increased platelet counts. The drug represents Teva's entry into the platelet-stimulating agent market via small-molecule oral delivery.
Growth12.4 years to LOE
Recent approval positions this as a growth-stage asset with opportunity for field team expansion and commercial infrastructure building.
Mechanism of Action
TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (also known as cMpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag
Started Jun 2026
150 enrolled
Immune Thrombocytopenia
Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP
Started Dec 2025
150 enrolled
Primary Immune Thrombocytopenia (ITP)
Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA
Started Jun 2025
70 enrolled
Aplastic Anemias
Bioequivalence Study of Revolade® Eltrombopag 50 mg
Started Jun 2025
30 enrolled
HealthyHealthy Donors
Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure
Started Feb 2025
78 enrolled
ITP - Immune Thrombocytopenia
Worked on ALVAIZ at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.